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ABSTRACT
Aim: Neuromuscular blocking agents (NMBAs) are used in a range of critical illnesses in
neonates and infants, despite a lack of guidelines and professional standards. This study
reviewed the current evidence base and ascertained UK practice regarding the continuous
use of these agents in this age range.
Methods: We reviewed the literature and carried out a telephone questionnaire of all
tertiary units in England and specialist children’s hospital neonatal units in the UK.
Results: No best practice guidelines or general consensus statements were found, and the
only randomised trial to feature an NMBA protocol expressed concerns about its use in
such young babies. Of the 56 units contacted, 54 (96.4%) shared information. Only three
of the 56 (5.4%) used intermittent boluses of NMBAs, 91.1% used NMBA infusions, 11
(19.6%) routinely used regular neuromuscular blocker pause to assess depth, and only
one (1.8%) used peripheral nerve stimulation monitoring. All the units carried out clinical
assessments, but only one (1.8%) had a written protocol.
Conclusion: There is a paucity of literature and professional standards to guide the safe use
of NMBAs in infants. Of the 54 units who participated in the survey, only one had a protocol
for using NMBAs in babies.
INTRODUCTION
The development of the neuromuscular junction in humans
starts as early as 8 weeks of gestation, with the transition
from polyneuronal to mononeuronal innervation com-
pleted by 25 weeks of gestation (1). For this reason,
clinicians use neuromuscular blocking agents (NMBAs),
or muscle relaxing drugs, when they intubate neonates (2),
to facilitate difficult ventilation and to allow wound healing
after surgery when movement would risk anastomotic
disruption. NMBAs can be given either by intermittent
boluses or by continuous infusion.
Neuromuscular blocking agents can prevent dangerous
neonate-ventilator asynchrony, such as in severe meconium
aspiration syndrome with persistent pulmonary hyperten-
sion or in the presence of an air leak. There is evidence that
asynchronous mechanical ventilation in preterm neonates
leads to a higher incidence of pneumothorax (3) and higher
peak transpulmonary pressures (4) and is likely to increase
the risk of intraventricular haemorrhage (5). The develop-
ment of assisted ventilation modes has helped to decrease
such risks, but a small population of neonates will continue
to struggle on a ventilator, despite adequate sedation. In
these situations, NMBAs can be helpful.
The use of an NMBA is also indicated in other situations,
including after surgery, to facilitate wound healing by
averting tension on tight anastomosis, for example, after
oesophageal atresia or bladder extrophy repair. In cardiac
units, NMBAs are used to decrease energy expenditure
during low cardiac output, for example after a cardiopul-
monary bypass or in myocarditis/cardiomyopathy. They
can also facilitate extracorporeal membranous oxygenation
(ECMO) in severe pulmonary hypertension or be used
when there is delayed sternal closure after bypass surgery.
Furthermore, NMBAs are useful during interhospital trans-
fers of intubated neonates, either because of the extent of
the baby’s illness or the unavailability of assisted ventilation
modes.
Neonates, however, have been shown to be relatively
sensitive to exposure to NMBAs in comparison to older
children. They display proportionately longer action times
(6) and therefore require smaller doses (7).
Neuromuscular blocking agent use is associated with
complications, including prolonged blockade through over
dosage (8), postventilation muscle weakness (9), hypoten-
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sion (10) and hypoxaemia (11). Nevertheless, the early use
of NMBAs in specific conditions has been shown to
minimise the side effects (12). Specific complications are
known to occur with depolarising NMBAs, such as succi-
nylcholine, including bradycardia (13) and potassium
release (14). Inadequate sedation or anaesthesia can lead
to awareness during neuromuscular blockade in those
undergoing procedures, which was the subject of a national
survey of anaesthetic practice in the UK with results
currently being awaited (15). Clearly, neonates and infants
cannot communicate such awareness, and particular vigi-
lance is necessary.
A structured approach to the safe administration and
surveillance of the effects of NMBAs is clearly optimal.
However, while consensus statements and accepted stan-
dards regarding NMBA use and assessment exist in both
adult and paediatric intensive care units (16), there seems
to be limited information available to guide those using
NMBAs in neonatal intensive care units (NICUs). There
are some supportive data regarding short-term efficacy of
intermittent NMBA use in neonates, but the long-term
effects remain unknown (17). Although first principles
suggest that an infusion seems appropriate to provide
continuous NMBA, intermittent boluses may be used
depending on the indications. In reality, there is little
evidence to support the use of continuous NMBA admin-
istration in neonates, although this seems to be a com-
monly used mechanism of delivery. Whatever the mode of
administration, close monitoring of efficacy seems war-
ranted. Again, there is little information available on how
best to implement this, in particular whether clinical
assessment, formal acceleromyography or peripheral nerve
stimulation monitoring (PNSM) using a train-of-four mon-
itor is optimal. In our NICU, in a specialist children’s
hospital, we regularly interrupt the administration of the
NMBA infusion to provide the patient with a drug holiday
until they shows signs that they are recovering from the
drug’s effect. PNSM is rarely used in neonates, although
electromyography is undertaken for formal neuromuscular
assessment.
Because there are so little data available regarding the
safe use of NMBAs in neonates, we wanted to ascertain
current NICU practice in the UK before further exploring
NMBA use.
METHODS
An online literature search for NMBA assessment in
neonates was performed using PubMed and NHS Evidence
(to Jan 2012), The Cochrane Library (2012), MEDLINE
(from 1966 to January 2012), EMBASE (from 1988 to
January 2012) and Cinahl (from 2005 to January 2012). The
search terms used were neuromuscular block, muscle
relaxant AND neonate, infant, NICU, SCBU.
A telephone survey of all tertiary NICUs in England and
specialist children’s hospital NICUs in the UK was per-
formed during daytime hours in May 2012. The list of
English tertiary NICUs was obtained from the National
Neonatal Audit Programme (www.rcpch.ac.uk/nnap), and
the list of specialist children’s NICUs was obtained from the
Paediatric Intensive Care Audit Network (http://www.
picanet.org.uk/).
We asked the nurse in charge to complete the survey, as
we felt this would provide realistic answers about what
actually happened in practice, although all were allowed to
consult their unit guidelines, if appropriate. A simple four-
item questionnaire was deliberately used to minimise
disruption to staff (Table 1). This covered: whether NMBA
protocols existed and were used, whether regular clinical
assessments were carried out while using NMBAs, the
methods used to assess the effects of NMBA (clinical
observations, PNSM, acceleromyography), and the use of
drug holidays – intermittent cessations of NMBA infusion –
to assess the depth of block, either by clinical movement or
by PNSM. We also engaged in a more general discussion
about the experience and frequency of NMBA use in the
unit, if time allowed.
RESULTS
The literature search showed no structured assessment of
the depth of NMBA in the 12 publications that were
featured in the Cochrane systematic review updated in 2009
(17). Six of these studies were randomised controlled trials
on the use of muscle relaxants in preterm infants that were
published more than 20 years ago.
We found one randomised controlled trial that compared
cisatracurium and vecuronium infusions in neonates and
small infants after congenital heart surgery and which used
routine PNSM to assess the NMBA block (18). In that
study, the depth of the NMBA was determined using
standard train-of-four monitoring applied over the ulnar
nerve and hand. The authors stated that: ‘In nearly all of the
neonates, the magnitude of the electromyographic response
in the adductor pollicis was too small to be detected by the
monitor. Therefore, all determinations of train-of-four
response were made by visual observation of thumb
movement’ (18).
No clinical practice standards or peer-reviewed guide-
lines for assessing the effects of NMBA in neonates were
found.
We also carried out a telephone survey of 56 units in
England and the UK, excluding our own. Most of the staff
were happy to reply to our questions, but two units refused
to share any information.
Table 1 Simple four-item questionnaire was used deliberately to
minimise staff disruption
Is there a protocol for NMBA use in your unit?
Do you apply PNSM (e.g. train-of-four)?
Do you apply regular clinical assessment while using NMBA?
Do you perform regular drug holidays?
NMBA = Neuromuscular blocking agents; PNSM = Peripheral
nerve stimulation monitoring.
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Of the 54 (96.4%) units that took part, only three (5.4%)
used intermittent NMBA boluses rather than continuous
infusions and did not have a PNSM or any other protocol in
place. Questions three and four were therefore not relevant
(Table 1).
The remaining 51 units (91.1%) of the 56 contacted used
and were familiar with NMBA infusions. They were used
occasionally in tertiary level NICUs and depending on case-
mix in the specialist children’s hospitals, with frequent use
in cases of congenital heart disease, ECMO and pulmonary
hypertension.
All the units clinically assessed babies on NMBA, but
only one (1.8%) had a written protocol in place.
Regular drug holidays to assess NMBA effect and depth
of blockade were routinely performed in 11 (19.6%) units,
but only one (1.8%) reported that they would further assess
the depth of the blockade by PNSM if a baby did not move
after 6 h on a drug holiday.
DISCUSSION
There are extensive data in the literature, as well as best
practice guidelines, regarding the use and monitoring of
NMBA in paediatric and adult critical care patients.
However, we found no peer-reviewed standards or guide-
lines in the literature that addressed, or validated, the
assessment of neuromuscular blockade in neonates. Patient
size limits the application of the standard monitoring
devices regularly used in larger children, although anaes-
thetist colleagues anecdotally describe assessing the depth
of NMBA by PNSM of the facial nerve in smaller patients
during operations.
The Cochrane database review of neuromuscular paral-
ysis in newborn infants receiving mechanical ventilation
was last updated in 2009, but we were unable to find any
more recent studies during our literature search. The six
randomised controlled trials in the Cochrane review were
more than 20 years old, from an era of less sophisticated
synchronised ventilation and intensive care in general.
None of them featured any NMBA administration and
assessment protocol.
We only found one study that included an NMBA
protocol and that was a study of infants who were
randomised to different NMBA agents after congenital
heart surgery. The study expressed concerns about applying
standard adult/larger child monitoring techniques to
infants (18).
It is, perhaps, surprising that there appears to be such
limited clinical and research evidence to guide safe and
effective practice for this important group of drugs in such a
complex intensive care population. As a consequence, the
pharmacodynamics and pharmacokinetics of neonatal
NMBA are poorly understood, as indeed are the influence
of prematurity and other complicating conditions on the
neonatal neuromuscular junction per se.
Clinical guidelines and standards to facilitate the consis-
tent and safe use of NMBA in neonates are surprisingly
absent. Because of this, the long-term effects of NMBA use
in this population are unknown.
It seems reasonable to state that we need to pay greater
attention to training neonatal staff in the use of NMBAs and
to creating protocols for their safe use and assessment. In
general, standardised protocols are particularly helpful for
treatment regimens that are either not regularly used or
perhaps poorly understood. This creates both confidence in
staff and a base for reporting outcomes and further
research.
Our telephone survey was well received, with 54 of the 56
(96.4%) units happy to participate, and many suggesting
that they would really like guidance to be in place to help
their practice. NMBAs are used, albeit infrequently, in
tertiary neonatal units, as both intermittent boluses and
continuous infusions. However, they are used more fre-
quently in specialist children’s hospital NICUs, which care
for infants with congenital heart disease, those receiving
surgery, including airway surgery, and patients with peri-
ECMO pulmonary hypertension.
However, the lack of any validated standards or guide-
lines is reflected in the fact that most units treating neonatal
patients do not have a NMBA protocol for their unit.
Clinically assessing the baby is still the main tool used by
NICU staff. Arguably, this should happen during drug
holiday periods, when the drug was not being administered,
but only a fifth of units did this.
CONCLUSIONS
There remains a clear lack of literature regarding the use
and assessment of NMBA in neonatal patients. Considering
the possible toxicity and side effects of these drugs, further
research into their effects on neonatal physiology is needed.
In view of this lack of evidence, there is also an urgent need
for clinical guidelines and standards for NMBA use in
neonates.
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